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cal trials 15; ‘chemoembolization liver + melanoma’, 60 
results, subgroup clinical trials 14; ‘radioembolization 
liver + melanoma’, 18 results, subgroup clinical trials 3. 
The term ‘chemosaturation liver’ was tested without in-
dication since only few publications exist and provided 
us with five results and only one clinical trial. Conclu-
sion: Despite many years of clinical use and docu-
mented efficacy on intra-arterial treatments of the liver, 
there are still only a few prospective multicenter trials 
with many different protocols. To guarantee the future 
use of these efficacious therapies, especially in the light 
of many systemic or surgical therapies in the treatment 
of non-colorectal liver metastases, further large rand-
omized trials and transparent guidelines need to be es-
tablished.
© 2015 S. Karger GmbH, Freiburg
Introduction
Arterial therapies of liver malignancy are commonly used tech-
niques employing catheter systems in the hepatic arterial route. 
They are based on the existence of arterial tumoral hypervasculari-
zation of macroscopic lesions which draw most of their blood sup-
ply from the hepatic artery whereas normal liver parenchyma is 
mostly perfused by the portal venous system. The first reports of 
successful intra-arterial liver treatment were published in the mid-
1970s [1]. Interestingly, early reports already mentioned the use of 
intra-arterial chemotherapy or radioactive isotopes to treat malig-
nant disease [2]. In these early studies symptom control and relief 
was reported in up to 65% of the patients. With the introduction of 
modern, specialized interventional units, micro-catheters, and sub-
specialized physicians the field advanced to a major player in the 
treatment of liver-dominant disease.
This overview describes the various intra-arterial treatment op-
tions of non-colorectal liver metastases, focusing on the use of 
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Summary
Background: The unique situation of the liver with arte-
rial and venous blood supply and the dependency of the 
tumor on the arterial blood flow make this organ an ideal 
target for intrahepatic catheter-based therapies. Main 
forms of treatment are classical bland embolization 
(TAE) cutting the blood flow to the tumors, chemoembo-
lization (TACE) inducing high chemotherapy concentra-
tion in tumors, and radioembolization (TARE) without 
embolizing effect but very high local radiation. These dif-
ferent forms of therapies are used in different centers 
with different protocols. This overview summarizes the 
different forms of treatment, their indications and proto-
cols, possible side effects, and available data in patients 
with non-colorectal liver tumors. Methods: A research 
in PubMed was performed. Mainly clinical controlled 
 trials were reviewed. The search terms were ‘embolization 
liver’, ‘TAE’, ‘chemoembolization liver’, ‘TACE’, ‘radioem-
bolization liver’, and ‘TARE’ as well as ‘chemosaturation’ 
and ‘TACP’ in the indications ‘breast cancer’, ‘neuroen-
docrine’, and ‘melanoma’. All reported studies were ana-
lyzed for impact and reported according to their clinical 
relevance. Results: The main search criteria revealed the 
following results: ‘embolization liver + breast cancer’, 
122 results, subgroup clinical trials 16; ‘chemoemboliza-
tion liver + breast cancer’, 62 results, subgroup clinical 
trials 11; ‘radioembolization liver + breast cancer’, 37 re-
sults, subgroup clinical trials 3; ‘embolization liver + neu-
roendocrine’, 283 results, subgroup clinical trials 20; 
‘chemoembolization liver + neuroendocrine’, 202 results, 
subgroup clinical trials 9; ‘radioembolization liver + neu-
roendocrine’, 64 results, subgroup clinical trials 9; ‘em-
bolization liver + melanoma’, 79 results, subgroup clini-
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bland transarterial embolization (TAE), transarterial chemoembo-
lization (TACE), transarterial radioembolization (TARE), and 
transarterial chemoperfusion (TACP) in different tumor entities.
Technique of Transarterial Embolization
Definition of TAE
TAE or bland embolization of intrahepatic arteries aims at re-
versible or irreversible blocking of hepatic arterial flow by using 
different embolic agents (e.g. polyvinyl alcohol (PVA) particles, 
spheres, or gelatin sponge). The pure mechanism of action is 
tumor ischemia. The dual blood supply of the liver provided by the 
hepatic artery and the portal venous system allows for blocking of 
the two blood systems without causing necrosis of the liver paren-
chyma. The target of TAE is the arterial blood supply of primary or 
metastatic tumors of the liver, and therefore tumors with predomi-
nant arterial blood supply seem amenable for TAE.
A variety of different embolic materials is currently available 
on the market. Gelfoam, a gelatin sponge, is a widely used embolic 
material commercially available as powder or as sheet of which 
small cubes or pledgets can be cut. However, the size of the pletgets 
is highly variable, and this may lead to a too proximal occlusion. 
Moreover, it is biodegradable and absorbed within 1–3 weeks; thus, 
it is regarded as temporary embolic material.
PVA particles are non-spherical particles of irregular shape and 
size which were mixed with diluted contrast media. PVA particles 
are seen as a permanent embolic material. Potential disadvantages 
are that they tend to aggregate which may also lead to too proximal 
embolization.
Spheres basically consist of an inert, elastic polymer that is cov-
ered with a hydrophilic surface. The shape is spherical, and calibra-
tion of sphere size is possible within very narrow ranges. Currently, 
a wide range of spheres are available from different manufactures, 
with sizes ranging from 40 to 1200 μm. The shape and coating 
make clumping less a problem than compared to non-spherical 
PVA. This allows for the spheres to reach the very distal capillaries 
of the tumor bed, resulting in a more profound ischemia. Figure 1 
illustrates a bland embolization of one metastasis of a neuroendo-
crine tumor (NET) with 40 μm microspheres.
TAE is generally used for targeted embolization, i.e., the tumor- 
feeding artery is selectively catheterized and embolized to avoid tis-
sue damage of the normal liver parenchyma.
Technique of Transarterial Chemoembolization
Definitions and Indications of TACE
TACE is a local catheter-based and minimally invasive thera-
peutic option for patients with unresectable and liver-dominant 
hepatic malignancies. By definition, TACE consists of a chemo-
therapeutic agent mixed with an embolic material, which is then 
selectively administered through the feeding arteries of the tumors. 
This combination allows for high intratumor drug concentrations, 
and the occlusion of the tumor-feeding arteries causes ischemic 
damage and necrosis of the tumor. Therefore, TACE seems amena-
ble in primary and secondary liver tumors, which derive their 
blood supply mainly from the hepatic artery (e.g. hepatocellular 
carcinoma (HCC), breast cancer liver metastases (BCLM), renal 
cell carcinoma, NET, melanoma, and bronchial carcinoma).
TACE is not uniformly defined in the literature. Different chem-
otherapeutic agents (e.g. doxorubicin, irinotecan, mitomycin-C, and 
cisplatin) as well as different embolic materials (iodized oil, gelatin 
sponge, PVA particles, spheres, and drug-eluting beads) are used. 
The conventional TACE (cTACE) consists of an injection of an 
emulsion of doxorubicin (usually 50–100 mg/m2) mixed with ethio-
dized oil (Lipiodol, Guerbet GmbH, Sulzbach, Germany), an iodi-
nated ester derived from poppy-seed oil, followed by the administra-
tion of embolic agents (e.g. gelatin sponge particles, PVA particles, 
or calibrated spheres) to achieve stasis in the target vessel [3].
With the introduction of drug-eluting beads (DC Beads, Bio-
compatibles, Farnham, UK) a new drug delivery and embolization 
system became available. Drug-eluting beads are non-resorbable 
hydrogel beads, available in different sizes (e.g. 100–300 μm, 300–
500 μm), that can be preloaded with chemotherapeutic agents, e.g. 
doxorubicin (DEBDOX TACE) or irinotecan (DEBIRI TACE). 
?? ?
Fig. 1. 54-year-old man with symptomatic liver 
metastases of a well-differentiated neuroendocrine 
tumor of the small bowel. a Superselective digital 
subtraction angiography over a 2.7F microcatheter 
(white arrow) of an aberrant hepatic artery to the 
liver segments IV and V shows two hypervascular 
tumors in these segments (black arrows). b Plain 
X-ray after transarterial bland embolization with 
40 μm microspheres (Embozene®; Celonova  
Biosciences, San Antonio, TX, USA) shows com-
plete stasis in the embolized tumors.
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Preclinical data of drug-eluting beads showed higher intratumor 
drug concentrations, a more sustained drug release into the tumor, 
and a low release of doxorubicin into the systemic circulation com-
pared to cTACE [4]. Results from the PRECISION V trial compar-
ing doxorubicin-loaded DC Beads with cTACE in patients with 
BCLC stage A/B HCC showed a trend towards improved tumor 
control, a significant reduction in serious liver toxicity, and a sig-
nificantly lower rate of doxorubicin-related side effects in the DC 
Bead group [3].
Pretreatment Considerations and Contraindications
All patients should obtain some cross-sectional imaging either 
with magnetic resonance imaging, computed tomography (CT), or 
positron emission tomography (PET)/CT to prove liver-dominant 
disease and to ensure that the portal venous system is patent. The 
latter is important due to the risk of necrosis and liver failure fol-
lowing arterial embolization in patients with portal venous throm-
bosis. Moreover, all patients should have laboratory tests including 
complete blood count, liver and kidney function tests, and coagula-
tion state [5]. It is known that a serum bilirubin level >34 μmol/l, 
>50% liver tumor involvement, and AST levels >100 IU/l are asso-
ciated with increased mortality following TACE [6].
Intervention, Technical Requirements, and Considerations
TACE is performed in dedicated angiography suites with local 
anesthesia at the puncture site. Moderate conscious sedation is 
rarely required. Antibiotic prophylaxis is not generally recom-
mended but should be considered in patients with bilioenteric 
anastomosis, biliary stents, or incompetent sphincter of Oddi [7]. 
A percutaneous retrograde femoral access with insertion of a 5–6 
French vascular sheath is most common. Due to the high preva-
lence of variant hepatic arterial anatomy of 12–49% [8], diagnostic 
angiography of the coeliac trunk and superior mesenteric artery 
should always be obtained at the time of first TACE. Filming 
should also include the portal venous phase to prove patency and 
hepatopetal flow of the portal venous system as well as to exclude 
collateral pathways. The mixture of chemotherapeutic agent and 
embolic material can be delivered in a selective, segmental, or lobar 
manner depending on number, size, and distribution of the tu-
mors. The use of microcatheters allows for very selective catheteri-
zation of tumor vessels and helps to avoid vasospasms, which may 
hamper drug delivery.
Complications Associated with TACE
Complications following TACE can occur in up to 10%. 
Postembolization syndrome (fever, nausea, pain) is most frequent 
(4.6%) but not necessarily classified as a complication [5]. Liver 
failure is seen in up to 2.3%. Patients with biliary stents or bilioen-
teric anastomosis are at higher risk (0–15%) for postprocedural ab-
scess than patients with functional sphincter of Oddi (1–2%). Inad-
vertent drug delivery to the gallbladder or gastrointestinal tract can 
cause cholecystitis (<1%) and gastrointestinal ulcers (<1%) [5]. 
Systemic side effects like skin discoloration (1.9–2.2%), mucositis 
(4.3–5.6%), and bone marrow suppression (5.4–5.6%) are relatively 
rare. Alopecia is almost absent (1.1%) with DEBDOX TACE 
though very frequent in patients who undergo cTACE (20.4%) [3].
Technique of Transcatheter Arterial Radio- 
embolization
Definitions and Indications of TARE
The principle of TARE is strongly associated with TACE. The 
main difference to TACE is the choice of local radiation instead of 
chemotherapy to achieve tumor control. High local radiation is de-
livered by microspheres containing or carrying Yttrium-90 (Y90, 
T1/2 64 h). Y90 is a pure beta emitter with high local energies de-
positing local radiation over a few millimeters up to 1,000 Gray in 
one session. Since the distance of radiation is very short, the radia-
tion burden of the normal liver is considered to be lower than 35 
Gray. In Switzerland, the treatment is used consequently in an out-
patient setting. However, since effects of radiation and chemother-
apy are biologically complementary, patient selection, patient in-
formation, technical intervention, and side effects are substantially 
different.
In every cancer treatment, selection of patients is most impor-
tant. In Switzerland, TARE is paid for patients with liver-domi-
nant, unresectable, chemorefractory liver metastases or HCC not 
amenable for TACE. Most often, indications of non-colorectal me-
tastases are breast cancer, NET/carcinomas, and melanomas, in ad-
dition to rare indications such as pancreatic cancer or sarcomas 
(the data for these indications will be presented in the course of 
this article).
However, as a result of the most recent studies, the situation 
might change in the near future. In our daily routine, patients after 
several lines of chemotherapy are the most often indications for 
TARE. Since many of these patients already suffer from side effects 
of multiple preexisting chemotherapies, meticulous choice regard-
ing the ECOG score, liver function, and extrahepatic spread is rel-
evant. As many of these patients are heavily pretreated, all our pa-
tients are primarily seen by an oncologist and then presented at the 
local tumor board. Most important factors are sufficient liver func-
tion, absence of ascites, and only moderately elevated bilirubin 
(<1.5 upper limit (UL)) and transaminases (<5 UL). Indications 
and contraindications are summarized in table 1.
Intervention, Technical Requirements, and Considerations
After having received written informed consent of the patient, 
the first angiography of TARE preparation is performed. The pri-
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mary angiography is used to plan the therapy as well as to identify 
and eventually coil aberrant vessels, e.g. gastric or duodenal arter-
ies. Before removing the catheter, a total of 180 MBq of Tc-99m 
microaggregated albumin (MAA) is infused to simulate the final 
therapeutic procedure. Patients are then transferred to the nuclear 
medicine department for whole-body single-photon emission 
computed tomography (SPECT) to predict lung shunting (e.g. in 
cirrhotic livers). A liver/lung shunt >20% is considered a contrain-
dication for TARE. However, free Tc-99m, e.g. in the ear/nose/
throat region or diffusely in the stomach, has to be considered as 
false-positive. There are several publications showing that the dis-
tribution of MAA in SPECT might predict the response and out-
come of TARE. However, data from our group showed that perfu-
sion CT prior to radioembolization predicts the overall survival 
(OS) of our patients [9]. Only after the planning procedure the se-
lective internal radiation therapy (SIRT) might be initiated. The 
procedure is shown in figure 2.
TARE can be performed using two different products, i.e. resin 
microspheres (Sirtex Medical Limited, North Sydney, Australia) or 
glass microspheres (BTG International Ltd, London, UK). Both 
products underlie the same mechanism of high local radiation via 
intra-arterial placement in the liver. The products differ in size, 
number of particles, radiation per particle, and variants of the ad-
ministration procedure. The dose is calculated via different models 
by either considering body surface area (BSA model) or liver volu-
metry or via dosimetric modelling. In large multicenter studies, 
mostly easy-to-use models are applied and must be used accord-
ingly in the respective setting (e.g. SIRFLOX study, adapted BSA 
model). TARE per se is performed in our institution in an outpa-
tient setting. Exceptions are large tumors or functional NET where 
the systemic response due to release of cytokines and hormones 
can be dramatic. The procedure has to be performed in specifically 
labelled angiography rooms which have to be cleared after the in-
tervention by the radiation protection staff. After the procedure, 
patients receive the ‘Bremsstrahlung Scan’ which allows the depic-
tion of local radiation. Alternatively, time-of-flight PET can also 
identify high local radiation over internal pair positron emission.
Patients are seen 4 weeks after SIRT in an outpatient setting. 
Imaging is not recommended earlier than 3 months after radiation. 
However, one must be aware that interpretation of imaging might 
be complicated after radiation and inflammation.
Complications Associated with TARE
TARE is a safe procedure in experienced hands. However, since 
many new treatment centers are founded in the light of rising evi-
dence, one must be aware of possible side effects. Most current side 
effects arise from systemic response to inflammation. Patients suf-
fer from fever, swelling, tiredness, and sometimes prolonged pain. 
Nevertheless, most of these side effects are of short duration, i.e. 
only a few days. Dangerous side effects might arise from misplace-
ment of the microspheres. Especially deposits of small amounts of 
spheres in the duodenum or in the gastric wall might produce 
long-lasting and painful ulceration or even perforation. This com-
plication has to be avoided at all circumstances by meticulous coil-
ing of all arteries at risk and exact catheter placement. A further 
dangerous complication is radiation-induced liver disease. This 
complication arises around 4 weeks after the therapy procedure 
and is primarily of clinical nature, mimicking a hepatic veno-oc-
clusive disease. This is a very rare but potentially life-threatening 
complication which must be treated in close collaboration with the 
hepatologists.
Technique of Transarterial Chemoperfusion/ 
Chemosaturation
Definitions and Indications of TACP
TACP is identical to other intra-arterial treatments benefiting 
from differential blood supply of liver metastases and normal liver 
tissue. The main difference is the continuous infusion of isolated 
chemotherapy (e.g. melphalan). This system allows a very high 
dose of local chemotherapy (chemosaturation) by means of subse-
quent chemo-isolation through a double-balloon catheter in the 
venous hepatic outflow.
This rather difficult procedure has only few indications and has 
to our knowledge only been tested in a series of uveal melanoma.
Intervention, Technical Requirements, and Considerations
The procedure is usually carried out under general anesthesia, 
and full anticoagulation is needed during the whole procedure. 
High doses of a chemotherapy drug are then infused directly into 
the liver via the hepatic artery infusion catheter over a period of 
approximately 30 min. During this time, blood leaving the liver 
passes through an extracorporeal filtration system that removes 
most of the chemotherapy drug before the blood is returned to the 
circulation via a catheter in the internal jugular vein. Since the 
Table 1. Indication and contraindications for TARE; official status in Swit-
zerland KLV Addendum 9.3. from July 1, 2010
Indication
Inoperable, chemotherapy-refractory liver tumors in which no other local  
ablative or embolizing therapy is indicated or has been non-effective
Indication through interdisciplinary hepatobiliary center with specialized 
surgery, interventional radiology
Signed patient consent form
Contraindications
Palpable ascites or other clinical signs of liver failure
Significant laboratory signs of liver failure (ALT, AST > 5 × ULN), bilirubin > 
1.5 ULN
Relevant hepato-pulmonary shunt (generally >20%)
Relevant, non-correctable reflux in stomach, duodenum, pancreas, or other 
intestinal organs
Dominant extrahepatic disease
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hemodynamic status changes during the procedure, an anesthetic 
team and a perfusion scientist are required for management.
Complications Associated with TACP
Adverse events resulting in death were reported in 4% in a study 
of 121 (5/121) patients, while serious neutropenia and thrombocy-
topenia were reported in 59% and in 80%, respectively, in the same 
study [9]. Furthermore, 17% had cardiovascular events (13 at the 
time of the procedure), and gastrointestinal events were reported 
in 11% (including gastritis, ulceration, perforation, bleeding, and 
gallbladder-related events). Moreover, patients may suffer from 
hemorrhage or hepatic events, making this procedure overall 
rather toxic.
Results
Breast Cancer Liver Metastases
BCLM are seen in up to 50% of all patients with metastatic 
breast cancer, and the presence of liver metastases is reported to be 
associated with poor outcome, with median survival rates of less 
than 6 months [10]. Newer epidemiological data show that median 
survivals of up to 16.3 months can be achieved with modern adju-
vant chemotherapy regimens [10]. The role of local therapies to the 
liver, such as liver resection, percutaneous ablative procedures, and 
liver-directed transarterial therapies, remains controversial as the 
presence of BCLM is generally seen as a disseminated disease re-
quiring rather systemic chemotherapy than locoregional therapy.
However, in selected patients with unresectable and liver-domi-
nant BCLM, palliation by transarterial therapies may be of interest. 
The following paragraphs provide an overview on the current re-
sults of TACE and TARE in patients with BCLM in metastatic 
breast cancer disease. To our knowledge, there are no data on TAE 
in patients with BCLM.
TACE for BCLM
Different TACE regimens for BCLM are described in the litera-
ture. A retrospective analysis by Giroux et al. [11] reported results 
of 8 patients who were treated by TACE due to pain (n = 4) and/or 
liver-dominant disease unresponsive to systemic chemotherapy. 
Only one patient suffered from extrahepatic disease, and 7 patients 
received systemic chemotherapy before TACE. Chemoemboliza-
tion was performed with a mixture of 100 mg cisplatin, 50 mg dox-
orubicin, and 10 mg of mitomycin mixed with ethiodized oil. Pa-
tients received a median of three TACE sessions. 5 patients (62.5%) 
showed regression of liver tumors and one showed stable disease. 3 
patients died within 3 months. The mean survival for the whole 
group was 20 months from the diagnosis of liver metastasis and 6 
months from the first TACE.
A study by Li et al. [12] compared TACE and systemic chemo-
therapy in 48 patients with BCLM, of whom 20 were treated by sys-
temic chemotherapy (cyclophosphamide, epirubicin, and 5-fluoro-
uracil) and 28 by TACE. Patients were treated with 5-fluorouracil 
and cisplatin followed by chemoembolization with a mixture of 
doxorubicin and iodized oil. The overall response rate was signifi-
?? ??
?? ?? ?
Fig. 2. Overview of the diagnostic workup of a 
74-year-old male with liver metastases in the right 
liver lobe of a high-grade gastric neuroendocrine 
carcinoma prior to TARE. a Digital subtraction 
angiography of coeliac trunk showing the large  
hypervascular tumor in the right lobe (black  
arrowheads) as well as a smaller tumor (white  
arrowheads) in segment VI. The gastroduodenal 
artery (black arrow) is patent. The right gastric  
artery was ligated during gastrectomy and cannot 
be appreciated on angiography any more. b Stain-
ing of the tumor continues to the portal venous 
phase. c Following coil embolization of the gas-
troduodenal artery (white arrow), the microcathe-
ter was placed in the proper hepatic artery and 180 
MBq of Tc-99m MAA were administered through 
the microcatheter. d Whole-body SPECT was  
acquired following Tc-99m MAA infusion. The 
calculated liver/lung shunt was 0.14. e Fused  
coronal image of SPECT showing Tc-99m MAA 
deposits in the liver metastases.
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cantly better in patients treated by TACE (35.7%) than in patients 
with systemic chemotherapy (7.1%, p < 0.05). The 1-, 2-, and 
3-year survival was better for TACE (63.04, 30.35, and 13.01%, re-
spectively) than for systemic chemotherapy (33.88, 11.29, and 0%, 
respectively). However, 9 patients in the TACE group only had sin-
gle liver metastasis and no extrahepatic disease, which might ex-
plain the good survival results. One patient died due to chronic 
renal and hepatic failure and one due to hepatic encephalopathy. 
Major limitations of the study were the lack of randomization and 
the fact that new systemic chemotherapies, e.g. with taxanes, were 
not tested against TACE.
The safety and efficacy of doxorubicin-loaded drug-eluting 
beads TACE (DEBDOX TACE) in patients with liver-dominant 
metastatic breast cancer was tested by Martin et al. [13]. The study 
population comprised 40 female patients with a total of 73 DEB-
DOX-TACE procedures. 57% of the patients had focal but stable 
extrahepatic disease (bone: n = 16; lung: n = 3; brain n = 2; pan-
creas n = 1). 62% of the patients had a tumor liver involvement of 
<25%; however, this was of a miliary and multifocal type. Concur-
rent systemic chemotherapy was present in the majority of pa-
tients. Adverse events were mostly limited to signs of a postemboli-
zation syndrome, except in one patient who required cholecystec-
tomy following extrahepatic DC Beads infusion. The overall re-
sponse rate at 3 months was 58% and then remained 50% at 6, 9, 
and 12 months following DEBDOX-TACE. The median progres-
sion-free survival (PFS) was 17 months, with a hepatic-specific PFS 
of 26 months. OS amounted to 47 months. Compared to first-line 
systemic chemotherapies with response rates of 30–65% and a PFS 
of 11 months [14], results of DEBDOX-TACE are encouraging.
A recently published phase II study with 43 patients analyzed 
TACE with gemcitabine in patients with BCLM [15]. The TACE 
regimen consisted of a mixture of gemcitabine (1,200 mg/m2), 
100–300 mg degradable starch microspheres, and 2–10 ml of lipi-
odol. 88.4% of the patients received three cycles of TACE in a 
4-week interval. 3 patients received only two cycles of intra-arterial 
gemcitabine due to tumor progression. Complete response (CR) 
and partial response (PR) was seen in 7%, stable disease (SD) in 
39%, and in 54% progressive disease was found. Median PFS was 
3.3 months (95% confidence interval (CI): 3.0–4.0). At 6 months, 
only 18% (95% CI: 7–46%) were free of progression. The estimated 
OS was 10.2 months (95% CI: 18–59%), and the estimated 1-year 
survival rate was 32%.
Another study evaluated three different TACE regimens in a 
total of 208 patients [16]. TACE regimens consisted of mitomycin-
C only (n = 76), mitomycin-C with gemcitabine (n = 111), and 
gemcitabine only (n = 21). Embolization was performed by mixing 
the chemotherapeutic agent(s) with lipiodol, followed by injection 
of 200–450 mg of starch microspheres (200–450 μm). TACE was 
performed at 4-week intervals (mean: 5.1 sessions; range: 3–25 ses-
sions). Of the three treatment regimens, the combination of mito-
mycin-C and gemcitabine performed best with PR in 17.12%, SD in 
49.55%, and progressive disease in 33.33%. Median and mean sur-
vival times were best after TACE with a combination of mitomy-
cin-C and gemcitabine, i.e. 24.8 and 35.5 months, respectively.
TARE for BCLM
There are only a few studies available which exclusively report 
on TARE in patients with BCLM. Table 2 provides an overview on 
these studies with regard to response rate, survival, and toxicity of 
TARE in patients with BCLM.
Disease control rates, defined as the sum of CR, PR, and SD, var-
ied from 70 to 98.7% in the mentioned studies. These results are 
Table 2. Overview of studies using TARE in patients with BCLM
Authors, year Number  
of patients,  
n
Type of microspheresa  
(mean activityb)
Assessment 
criteriac
Complete  
response,  
%
Partial  
response,  
%
Stable 
disease,  
%
Progressive 
disease,  
%
Median survival,  
months
Mean  
survival, 
months
Bangash et al.,  
2007 [34]
27 glass  (2.05 ±1.06 GBq) WHO 39 39 52  8.8 nr nre
Jakobs et al.,  
2008 [17]
30 resin  (1.896 GBq) RECIST  0 61 35  4 11.7 (significantly  
better for patients  
with CR or PRd)
9.6
Haug et al.,  
2012 [35]
58 resin (1.77 ± 0.49 GBq) RECIST  0 25.6 62.8 11.6  6.7 nr
Gordon et al.,  
2014 [36]
75 glass (1.52 GBq) RECIST 35.3 63.4  1.5  6.6 nr
Saxena et al.,  
2014 [37]
40 resin (1.67 ± 0.36 GBq) RECIST  5 26 39 29 13.6 nr
a Glass = Glass microspheres (TheraSphere; BTG International Ltd, London, UK). Resin = Resin microspheres (SIR-Spheres; SIRTex Medical Limited, Sydney, 
Australia).
bMean activity infused during TARE. Data are displayed in gigabecquerel (GBq).
cAssessment criteria of response. WHO = World Health Organization; RECIST = response evaluation criteria in solid tumors.
dCR = Complete response; PR = partial response according to RECIST.
enr = Not reported.
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actually very encouraging, considering the fact that the included pa-
tients suffered from advanced disease especially in the liver and had 
several chemotherapies. Jakobs et al. [17] reported a median OS of 
11.7 months (range: 3.0–45.1 months). Patients who responded to 
TARE showed a significantly better survival than those who did not 
respond (23.6 vs. 5.7 months, p = 0.005). There was no significant 
difference in survival for patients with and without extrahepatic 
disease.
Neuroendocrine Tumor Liver Metastases
TAE for NET
TAE for NET might be indicated in patients with defined lesions 
and low proliferation rates as well as in functional tumors. The first 
publication of TAE in patients with liver metastases of NET was by 
Carrasco et al. [18] where a response to TAE was observed in over 
90% of the patients, with a mean response of 11 months. High tumor 
response rates with regard to radiological changes as well as bio-
chemical response were subsequently published in many case series, 
and the median OS differed from 10 to 80 months [19]. In a large 
study in 107 patients with carcinoid syndrome, a reduction of asso-
ciated symptoms was described in 80% of the patients [20]. Further 
studies considering the safety of TAE in patients with hepatic metas-
tases of NET reported rare adverse events such as ischemia of the 
biliary tree and postembolization syndrome. In the latter review, 
complications were seen in 125/896 (14%) [19]. Overall, TAE seems 
to be an effective and safe procedure in patients with small to mod-
erate tumor involvement in the liver and non-compromised liver 
function. Patients with carcinoid symptoms and associated cardiac 
disease must be treated with specific caution since treatment-related 
mortality might be higher due to hormonal release.
TACE for NET
In contrast to TAE, TACE does rely on the combination of 
chemotherapy and embolization of liver metastases. The most 
commonly used chemotherapies are anthracyclines such as doxo-
rubicin, combinations of cisplatin, doxorubicin, and mitomycin-C, 
or streptozotocin. Despite the moderate activity of chemotherapy 
especially in low proliferative NET, TACE in NET has high activity 
since the concentration of the cytotoxic agent in combination with 
embolization is 100-fold [21]. When looking at the evidence, how-
ever, there are just a few trials focusing on the isolated use of TACE 
and not TAE. Pitt et al. [22] compared the outcomes of TACE ver-
sus TAE in 100 patients with carcinoid or islet cell tumors. TACE 
was performed using cisplatin, doxorubicin, and mitomycin-C. No 
differences were found regarding OS, response rates, and 5-year 
survival. There were no differences in complications (2.4 vs. 6.6%) 
and mortality rates (0.8 vs. 1.8%) in this trial. A large study by 
Bloomston et al. [23] analyzed 122 patients with metastatic carci-
noid tumors undergoing TACE with a median follow-up of 21.5 
months. Complications occurred in a large fraction of 23%, and 
periprocedural mortality was 5%. This study concludes that TACE 
offers good symptom palliation and long-term survival. However, 
it should be used cautiously in patients with large tumor burden. A 
recent trial using drug-eluting beads (DEB-TACE) in patients with 
liver metastases of NET showed a reduction of the targeted lesion 
by 78% when taking criteria of the European Association for the 
Study of the Liver into account. However, 54% of the patients were 
developing biloma as a substantial side effect [24].
TARE for NET
In contrast to TAE and TACE, TARE is not embolizing the 
tumor lesions and is therefore generally well tolerated even in 
higher tumor burden. Thus, the major aim of TARE is not to com-
pete with TACE or TARE but to treat different situations with 
large tumors since it is generally, if well used, a more secure treat-
ment with less side effects. Many phase II studies have already been 
published. The largest series by Kennedy [25] showed a PR in 61% 
of the patients with low toxicities, mainly fatigue (6.5%). A recent 
study by Peker et al. [26] demonstrated the safety and effectiveness 
of the treatment of unresectable liver NET, with 1- and 2-year sur-
vival rates of 71 and 45%, respectively. A recent meta-analysis by 
Devcic et al. [27] showed an average objective response of 50% and 
a weighted average disease control rate of 86%. This large meta-
analysis considered TARE as an effective treatment option for pa-
tients with hepatic metastatic NET with high response rates and 
prolonged survival.
Some experts still consider TARE in NET as an experimental 
procedure. However, in the light of current data and its relation to 
existing data for TACE and TAE, we strongly suggest to regard 
TARE not as competition to existing therapies but as a safe and ef-
fective complementation especially in larger tumor burden.
Melanoma Liver Metastases
TAE/TACE for Melanoma Liver Metastases
To our knowledge, there is no data for bland embolization in 
melanoma liver metastases. Some studies have been published on 
hepatic intra-arterial chemotherapy (HIAC) and TACE in mela-
noma liver metastases. Most of the HIAC trials were retrospective 
or phase II trials by Becker et al. [28] combining fotemustine with 
sequential IFNα + IL-2; here, an overall response of 22% with a 
median OS of 12.1 months was revealed. A larger phase III trial in 
ocular melanoma in 171 patients was only published as an abstract 
and showed an overall response of 11% and an OS of 14.6 months 
[29]. TACE using various chemotherapies such as cisplatin, pacli-
taxel, fotemustine, doxorubicin, or even immunogenic agents such 
as GM-GSF resulted in response rates of up to 39% in a retrospec-
tive series combining TACE with HIAC [30]. However, the pa-
tient series remained small and, to our knowledge, there is no 
phase III trial focusing on the efficacy of TACE in this patient 
population.
Chemosaturation for Melanoma Liver Metastases
Chemosaturation isolates the hepatic perfusion, thus establish-
ing high doses in the liver. The agent commonly used is melphalan. 
Arterial Therapies of Non-Colorectal Liver 
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A large retrospective study with 125 patients by Gupta et al. [31] 
led to 11% PR, 16% minor responses, an SD of 65%, and progres-
sive disease in 8%. However, this is a complicated procedure with 
long procedure times of up to 8 h, considerable morbidity, and 
prolonged hospital stay of up to 10 days [32].
TARE for Melanoma Liver Metastases
A recent study by Xing et al. [33] analyzed the efficacy of TARE 
compared to best supportive care in 58 patients with liver metasta-
ses of melanoma. Both groups were well balanced. The median OS 
was highly significantly better in the treatment group (19.9 vs. 4.8 
months, p < 0.0001). Toxicity was rather low with abdominal pain 
in 17.9%, fatigue in 14.3%, and self-limiting grade III bilirubin tox-
icity in 10.7%.
Conclusion
In conclusion, intra-arterial therapies in the form of TAE, 
TACE, or TARE are secure and highly effective. Each of these dif-
ferent modalities must be chosen in regard to available data but 
also according to personalized patient level. However, more stan-
dardized treatment protocols and phase III data are desperately 
needed to establish transparent and useful guidelines.
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